These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27502323)

  • 1. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
    Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
    Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
    Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
    Ng R; Hasan B; Mittmann N; Florescu M; Shepherd FA; Ding K; Butts CA; Cormier Y; Darling G; Goss GD; Inculet R; Seymour L; Winton TL; Evans WK; Leighl NB; ; ;
    J Clin Oncol; 2007 Jun; 25(16):2256-61. PubMed ID: 17538170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
    Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
    J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
    Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
    J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
    Tsao MS; Sakurada A; Ding K; Aviel-Ronen S; Ludkovski O; Liu N; Le Maître A; Gandara D; Johnson DH; Rigas JR; Seymour L; Shepherd FA
    J Thorac Oncol; 2011 Jan; 6(1):139-47. PubMed ID: 21107284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.
    Mu L; Liu F; Fang Y; He M; Yang M
    BMJ Open; 2024 Aug; 14(8):e081270. PubMed ID: 39179275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
    Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
    PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
    van den Hout WB; Kramer GW; Noordijk EM; Leer JW
    J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
    Zou ZQ; Du YY; Sui G; Xu SN
    Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
    Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
    Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
    J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.